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ABSTRACT 
No appreciable improvements in incidences and mortality rates of women with ovarian 
cancer have been made over the last 40 years; this fact alone indicates that scientists and 
clinicians lack the adequate tools to conquer this deadly disease.  The American Cancer 
Society estimates that more than 22,000 women will be diagnosed with ovarian cancer 
this year, and over 14,000 deaths will be attributed to this disease; this translates to 1 out 
of every 75 women in the US being diagnosed with ovarian cancer, and of those 
diagnosed, over 60% will die from the disease.  Lack of a more predictive animal model 
has been an obstacle to progress in ovarian cancer research.  It is hypothesized that 
laying hens, though not fully characterized, could be an optimal animal model for the 
study of human ovarian cancer initiation, progression, therapy and relapse.  Domestic 
laying hens (Gallus gallus domesticus), spontaneously develop ovarian cancer at a high 
incidence.  
In an effort to better characterize ovarian cancer in laying hens, we created a surgically 
implantable, biocompatible port using 3D printing technology, which allows for repeated 
access to the ovary for laparoscopic serial sampling, observation, and imaging. With the 
ability to follow laying hens via easily accessible ports throughout their lifespan, our 
hope is to be able to detect when they develop ovarian cancer, as well as discover early 
diagnostic techniques for this disease. 
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The fact that laying hens are a spontaneous ovarian cancer model with a high incidence 
of disease suggests their usefulness as a preclinical animal model.  Little is known about 
tolerability and efficacy of chemotherapeutics in the laying hen or in avian species in 
general.  We administered a 6-week paclitaxel treatment to assess chemotherapeutic 
efficacy in 4.5-year-old laying hens suspect for ovarian cancer.  Magnetic resonance 
imaging (MRI) and positron emission tomography–computed tomography 
(PET/CT) were used to identify cancerous laying hens as well as to assess changes in 
tumorigenesis throughout treatment.  Results are indicative of chemotherapeutic 
tolerability and efficacy, as well as the value of using a non-invasive method for 
diagnosis of cancer within the coelomic cavity, further suggesting the potential of the 
laying hen as an animal model for preclinical research.  
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CHAPTER I 
INTRODUCTION 
 
Ovarian cancer is a disease caused by an uncontrolled division of abnormal cell growth 
that in 80% of patients has already metastasized by the time of diagnosis.  If caught 
early, the prognosis for survival increases dramatically.  There are 3 main types of 
ovarian cancer, germ cell (egg or ova), stromal cell (structural and hormone producing 
tissue), or epithelial cell cancer (the surface or epithelium layer).  The most common 
type of ovarian tumor is epithelial with 90% of ovarian cancers developing from the 
epithelium [5].  Epithelial cell tumors are further classified into 4 histologic subtypes 
starting with the most common: serous (most common), mucinous, endometrioid, and 
clear cell.  The histologic types of epithelial ovarian cancers differ in clinical behavior, 
descriptive epidemiology, and genetic origins [1].  In fact, some of the complexity of 
this disease is due to the heterogeneity of the more than 100 histopathologic subtypes of 
ovarian cancer [2].  Some tumors are benign (non-cancerous) and never spread beyond 
the ovary however if the tumor is malignant (cancerous) the tumors can spread to other 
organs and locations throughout the body.  All women are at risk for ovarian cancer.  
There is a correlation of a woman’s risk for developing ovarian cancer to the number of 
ovulations she has had in her lifetime [3].  There are some known factors for increased 
risk of ovarian cancer such as a family history, being post-menopausal, obesity, use of 
infertility drugs, women who have not had children, or those who have never used oral 
contraceptives [4].  If there is a family history of ovarian cancer, a woman could request 
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genetic testing to identify mutations in BRCA1 and BRCA2 genes (breast cancer gene 1 
and 2) as it has been predicted that approximately 30% of those who have mutations in 
BRCA1/BRCA2 will get ovarian cancer by the age of 70 [4]. 
 
Ovarian cancer in women is so deadly because it is extremely difficult to detect at early 
stages.   The ambiguous symptoms of this disease mimic many other common 
conditions.   Per the American Cancer Society only 19% of ovarian cancer cases are 
diagnosed before there is metastatic spread outside the ovary.  The most common 
ovarian cancer symptoms are bloating, pelvic or abdominal pain, difficulty eating or 
feeling full too quickly, as well as changes in urinary urgency and frequency [5].  These 
symptoms are largely due in part to either an ovarian mass already formed or the 
presence of ascites fluid in the abdomen putting pressure on other organ systems. The 
presence of ascites correlates with the peritoneal spread of ovarian cancer and is 
associated with poor disease prognosis [6].   Less common symptoms may include back 
pain, constipation, menstrual changes, unexplained weight loss or gain, or unusual 
fatigue [5].  None of these symptoms are usual causes for a woman to feel alarmed or 
seek immediate medical attention.  At the time of diagnosis, in most cases, a woman is 
already at late stage cancer with metastatic spread outside of the ovaries at which point 
she will be faced with a 60% mortality rate.      
 
There is no screening assay to detect early stage ovarian cancer.   Routine screens such 
as yearly pap smears identify cervical cancer, but do not detect ovarian cancer.  There 
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are no blood tests to detect ovarian cancer.  When a woman reports any of these mild 
symptoms to her physician, it is at the patient and physician’s discretion to investigate 
further.  Once symptoms become problematic the usual course of action is to perform a 
pelvic examination which does not detect early stage cancer however, if abnormalities 
are found in the size of the ovary, further investigation using imaging modalities is 
warranted.    If the pelvic exam is abnormal, follow-up would be performed with 
transvaginal ultrasound (TVU) and a CA 125 (cancer antigen 125) blood test.  CA 125 
(also known as mucin 16 or MUC 16) is one of the most commonly used blood markers 
associated with ovarian cancer blood markers used, however, due to both its high false 
positive and false negative rates, the CA 125 blood assay is not reliable for screening.  
Elevated CA 125 levels in the blood are not predictive nor an accurate measure of cancer 
so it is most commonly used as a measure of change over the course of treatment rather 
than for diagnostic purposes.   The next treatment step would be surgical excision of the 
ovarian mass, followed by histological examination and grading.     
 
There has not been any appreciable improvement in early detection, diagnosis, or 
treatment of ovarian cancer in decades, despite improved knowledge of etiology, 
surgical advances, and improvements in chemotherapy [7].   Development of a screening 
test for early diagnosis would help tremendously in reducing mortality rates.  If ovarian 
cancer is diagnosed (and treated) before the cancer has spread outside the ovary (stage I), 
the 5-year survival rate is greater than 92% [5].    The standard model systems that exist 
to study ovarian cancer may also be the very obstacle preventing rapid progress.   
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Tumor-derived cell lines can play a critical role in facilitating in vitro studies of cancer 
biology; however, in vivo animal models can more accurately predict molecular 
characteristics of primary tumors, and provide a more pertinent preclinical testing 
platform [8].  Inadequate animal models that do not mimic the natural course of disease 
can explain, at least in part, the lack of progress toward diagnosis, early detection and 
improved treatments for ovarian cancer.   The most commonly used animal model for 
ovarian cancer research is either the genetically engineered mouse (GEM) or the 
immunodeficient mouse used for xenograft studies with human cancer cells.  Both the 
GEM models and xenograft models can further our understanding of key mechanisms 
facilitating tumorigenesis, enhanced imaging and treatment modalities [9].    GEM 
models most commonly (transgenic or knockout mice) have either an over-expressed or 
deleted gene of interest to determine the role of a particular gene in disease.  
Additionally, some GEM mice require the use of a drug or chemical to induce changes 
that lead to progression of disease.  The GEM mouse has great utility; however, the 
unnatural nature of the model’s genetic makeup is unable to mimic that of spontaneously 
occurring ovarian cancer within a normal human population.   Xenograft studies require 
the use of immunodeficient mouse strains such that the human cancer cells that are 
implanted are not rejected.  Ovarian cancer is not a disease that occurs naturally with a 
large quantity of cells instantly appearing under the skin or in the animal, nor is it a 
disease found only in women with abnormal immune systems.  The xenograft model has 
utility for drug testing using human cancer cells that can be propagated in a live animal 
however, it is not without problems.  In this model, the vasculature that builds around 
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the injected bolus of cells does not mimic that occurring during the normal progression 
of ovarian cancer.  Drug delivery is no doubt impacted by the inherent development of a 
tumor from implanting a large number of tumor cells (1-10 x10^6 cells) instantly into 
the mouse. Tumor development is highly variable depending on cancer cell type, tissue 
culture conditions, and implant location.  The unnatural and manipulated animal models, 
such as the GEM or xenograft mice certainly have their unique utility, but both also have 
significant drawbacks.  
 
The chicken model, though not fully characterized, is the only animal model that gets 
ovarian cancer spontaneously at a high incidence.  The laying hen could be the optimal 
animal model for the study of human ovarian cancer initiation, progression and therapy.  
Domestic laying hens (Gallus gallus domesticus), spontaneously develop ovarian cancer 
at a high incidence between 2-7 years of age [10].  This is thought to occur due to 
incessant ovulations leading to repeated DNA damage and repair of ovarian epithelial 
cells with ovarian cancer being directly related to the number of ovulations over time 
[11].  Women ovulate every 28 days whereas a laying hen ovulates almost every day 
(approximately every 27 hours), giving rise to higher rates of ovarian cancer in a much 
shorter time frame.  This theory correlates to humans, where ovarian cancer primarily 
develops in post-menopausal women 63 years of age or older.   Several studies have 
pointed out striking similarities in tumor types, protein and gene expression, and 
histologic appearance as well as symptoms in common between humans and chickens 
with ovarian cancers. 
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The laying hen model use in research on ovarian cancer has not been fully characterized, 
though it is becoming of increasing interest due to the spontaneous nature and high 
incidence of the disease.  Increased awareness over the last decade has brought the 
laying hen into the biomedical spotlight for ovarian cancer research even though it has 
been known for well over 80 years that laying hens have a high incidence of spontaneous 
ovarian cancer [12,13,14].  Fredrickson showed in 1987, within three different aged 
populations of laying hens that ovarian adenocarcinoma was not only the most common 
type of cancer found in 466 birds aged 2.5 to 7 years of age, but also that there was an 
increasing rate of this cancer as the birds aged, with the oldest group of birds having 
greater than a 34% incidence [14].  Eilati et al. found an increasing incidence ranging 
from 0% at 1 year of age to as high as 65% by 3 years of age in random samples of 20 
birds per time point from a colony of 600 laying hens [15,16].   These findings further 
support the incessant ovulation hypothesis claiming that ovarian cancer in both humans 
and laying hens is correlated to the number of lifetime ovulations, and with increasing 
ovulatory events there is increasing inflammation which makes surface epithelial cells 
prone to malignancies [18].   Additionally, in a study performed by Giles and co-workers 
comparing normal, wild-type laying hens to a mutant strain of hens known as ‘restricted 
ovulators’ there was a direct correlation between the number of ovulatory events and the 
incidence of ovarian cancer in chickens [19].   It is known that factors causing a 
reduction in ovulatory events such as birth control pill use, pregnancy and breastfeeding 
also reduce the risk of females developing ovarian cancer this also holds true with the 
laying hen as seen in a study done by Trevino et al. where a significant reduction in 
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ovarian cancer incidence was seen when a progestin treatment was administered over 
age-matched controls [20].  Carver et al. found a 5-fold reduction in epithelial ovarian 
cancer of laying hens fed a reduced-calorie diet (causing a reduction in ovulation) over 
the control group in comparison to the full-calorie control group [21].   
 
An increasing number of studies have pointed out remarkable similarities between 
humans and the laying hen regarding morphologic, molecular and epidemiologic 
characteristics, as well as disease progression in common between human and laying 
hens with ovarian cancer.  CA-125, also known as mucin 16, or MUC-16, is the most 
commonly used ovarian cancer biomarker used, however, it is not accurate enough to be 
used as a stand-alone screening assay for women due to variability in both false positive 
and false negative results. CA-125 levels have been found to be elevated in women with 
ovarian cancer but also as a consequence of endometriosis, pregnancy, and different 
stages of their menstrual cycle [22].  Its widely used for a measure of treatment efficacy 
rather than as a predictive assay due to the nonspecific results.  CA-125 was shown to be 
highly expressed in 90% of cells isolated from 15 laying hen ovarian tumors that were 
extracted from approximately 2-year-old hens, but not detectable in normal hen ovaries 
[23].  Mutations in p53, a tumor suppressor gene, have shown to have similar 
abnormalities in common between human and hen ovarian cancers.  One group 
examined alterations in the p53 tumor suppressor gene in chicken ovarian 
adenocarcinomas and found that 96% of 4-year-old birds versus 14 percent of 2-year-old 
birds had p53 mutations [24].  This shows a correlation to the reported 96% incidence of 
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human ovarian cancers (high grade serous tumors) in women having mutations in p53 
[25].   E-cadherin, an adhesion molecule, has been found to be upregulated in human 
ovarian cancers and found by Ansenberger et al. reported significantly greater 
abundance of E-cadherin protein in cancerous ovarian tissue of laying hens when 
compared to normal ovarian tissue [26].   Overexpression of E-cadherin and VEGF 
(vascular endothelial growth factor) plays a role in development of ascites fluid 
formation and dissemination of human ovarian cancer [27].  VEGF mRNA was shown 
to be increased in ascites fluid in cancerous laying hens [28].   Mesothelin is a protein 
normally present in mesothelial cells at low level; however, in human ovarian cancer 
cells and some other cancers this protein is over-expressed.  Yu et al. found MSLN 
mRNA in 57% (12/21) of hen ovarian tumors with none being expressed in normal 
ovarian tissue, and of those with MSLN mRNA 44% also had circulating anti-mesothelin 
antibodies [29].  Claudins (CLDNs) are a family of cell membrane proteins that play an 
important role in tight junction formation between cells and cell membranes.  In human 
ovarian cancer, a number of claudin proteins are over-expressed [30].  This over-
expression is also observed in laying hens that had more than 700-fold increase in 
CLDN10 mRNA in cancerous ovaries when compared to normal ovaries [31].  Matrix 
metalloproteinases (MMPs) are involved in protein degradation and associated with 
promoting invasion, angiogenesis, and metastasis of cancer cells, with several the known 
MMP sub-types showing increased expression in reproductive cancers [32].  Choi et al. 
found that in cancerous ovaries of laying hens there was a 16-fold higher expression of 
MMP3 mRNA than in normal ovaries and suggested there may be applications for its 
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use as a marker for ovarian cancer in chickens [33].   There are several novel biomarkers 
for ovarian cancer in the laying hen however, many show specificity to both stage of 
cancer and its histologic sub-type, so their broad application for ovarian cancer detection 
may be limited.  However, their use for monitoring progression of disease with treatment 
should be investigated further.   Alpha 2 macroglobulin (A2M), secreted phosphoprotein 
1 (SPP1), and SERPINB11 may be useful as potential biomarkers in monitoring efficacy 
of treatment in chicken endometrioid cancer as its expression is up-regulated in 
cancerous but not normal ovaries [34,35].   Up-regulation of cyclooxygenase 2 (COX-2) 
has been reported to occur in human ovarian cancer and to be associated with poor 
prognosis [36].  Eilati et al. showed an up-regulation of both COX-1 and COX-2 
enzymes as a function of laying hens age and an increase in a pro-inflammatory 
prostaglandin E2 (PGE₂), the downstream product of the COX enzymes. In addition, 
they noted further increases in COX-1 and PGE₂ in cancerous ovaries [16].   
 
There have been many studies showing histological commonalities between the laying 
hen and human ovarian tumors.  Rodriguez-Buford et al. showed that several antibodies 
against antigens that are frequently expressed in human ovarian tumors were cross-
reactive in the laying hen [37].  Bradaric et al. compared normal and cancerous sections 
of laying hen ovaries to assess tumor type and stage as well as CD4, CD8 and Bu-1a 
counts of immunostained cells and determined that there were significantly more 
immune cells in cancerous versus normal ovaries [38].  The four histologic subtypes of 
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ovarian cancer in humans (serous, mucinous, endometrioid, and clear cell) occur in 
ovarian tumors of laying hens [10]. 
 
The literature points to the fact that laying hens, though not commonly used, show great 
potential for advancing progress in ovarian cancer.  Our research aims to further validate 
this model and show how its application, benefits the study of ovarian cancer.   
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CHAPTER II 
DEVELOPMENT OF 3D PRINTED PORTS FOR REPEAT OVARIAN 
IMAGING AND BIOPSY IN DOMESTIC LAYING HENS (Gallus gallus 
domesticus): A SPONTANEOUS MODEL OF OVARIAN CANCER 
 
 
Synopsis 
No appreciable improvements in mortality rates of women with ovarian cancer have 
been made over the last 40 years [39].  Lack of a predictive animal model has been 
attributed as an obstacle for progress in ovarian cancer research.  It is hypothesized that 
laying hens, though not fully characterized, could be the optimal animal model for the 
study of human ovarian cancer initiation, progression and therapy.  Domestic laying 
hens (Gallus gallus domesticus) are the only animal model that spontaneously, and with 
high incidence, develop ovarian cancer [10].  In effort to improve its practical usefulness 
and to further validate this model, using 3D printing technology, we fabricated a 
surgically implantable port that allows for repeat access to the ovary for serial sampling, 
observation and imaging. With the ability to easily follow laying hens via accessible 
ports, our goal is to be able to detect onset of ovarian cancer, as well as discover early 
diagnostic techniques.  This port also allows repeat access to the coelomic cavity of the 
hen for other applications (such as chemotherapeutic delivery).  Finally, it holds the 
potential to benefit other areas of poultry research (renal, intestinal or oviductal etc.).   
Our device has been implanted in multiple birds for over one year without complications 
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or rejection showing the potential to offer easy ovarian access over an extended period 
of time and perhaps even the life of the animal.  
Introduction 
Ovarian cancer ranks fifth in cancer deaths among women; the high mortality associated 
with this disease is due to late diagnosis as well as ineffective treatment and preventative 
therapies.  The American Cancer Society estimates that 1 out of every 75 women in the 
US will be diagnosed with ovarian cancer, and that of those diagnosed over 60% will die 
from the disease.  These statistics are alarming, and a growing body of evidence is 
pointing to the model scientists commonly use, the mouse, as being one of the biggest 
obstacles to progress.   
 
Ovarian cancer is a disease caused by an uncontrolled division of abnormal cell growth 
in the ovaries of woman.    The most common type of ovarian tumor is epithelial with 
90% of ovarian cancers developing from the epithelium [5].  Epithelial cell tumors are 
further classified into 4 histologic subtypes starting with the most common: serous, 
mucinous, endometrioid, clear cell.  The histologic types of epithelial ovarian cancer 
differ in clinical behavior, descriptive epidemiology, and genetic origins [1].  In fact, 
some of the complexity of this disease is due to the heterogeneity of the more than 100 
histopathologic subtypes of ovarian cancer [2].  Some epithelial cell tumors are benign 
and never spread beyond the ovary, however if the tumor is malignant the tumors can 
spread to other organs and locations throughout the body. Determining the cell of origin 
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in ovarian cancer is difficult, there is debate whether the epithelial cells originate from 
the oviduct or the ovary because epithelial cells can undergo epithelial to mesenchymal 
transition where the epithelial cells from either tissue can migrate to the other [40].   
All women are at risk for ovarian cancer.  There is a correlation of a woman’s risk for 
developing ovarian cancer with the number of ovulations she has had in her lifetime [3].  
Ovarian cancer in women is so deadly because it is extremely difficult to detect at early 
stages.   The ambiguous symptoms of this disease mimic many other common 
conditions.   Per the American Cancer Society only 19% of ovarian cancer cases are 
diagnosed before there is metastatic spread outside the ovary.   
 
There is no screening assay to detect early stage ovarian cancer.   Routine screens such 
yearly pap smears identify cervical cancer but do not detect ovarian cancer.  There are 
no blood tests to detect ovarian cancer.  There has not been any appreciable 
improvement in early detection, diagnosis, or treatment of ovarian cancer in decades 
despite improved knowledge of etiology, surgical advances, and improvements in 
chemotherapy [7].   Development of a screening test for early diagnosis would help 
tremendously with reduction in mortality rates.  If ovarian cancer is diagnosed (and 
treated) before the cancer has spread outside the ovary (stage I), the 5-year survival rate 
is greater than 92% [5].     
 
The standard model systems that exist to study ovarian cancer may also be the very 
obstacles preventing rapid progress.   Tumor-derived cell lines can play a critical role in 
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facilitating cancer biology in vitro studies; however, in vivo animal models can more 
accurately predict molecular characteristics of primary tumors, and represent a more 
pertinent pre-clinical testing platform [8].  Inadequate animal models that do not mimic 
the natural course of disease may be partly to blame for the lack of progress toward 
disease diagnosis, early detection and improved treatments for ovarian cancer.   The 
most commonly used animal model for ovarian cancer research is either the genetically 
engineered mouse (GEM) or the immunodeficient mouse used for xenograft studies with 
human cancer cells.   However, there is another option.  The laying hen model, though 
not fully characterized, is the only animal model that gets ovarian cancer spontaneously 
at a high incidence.  The laying hen could be the optimal animal model for the study of 
human ovarian cancer initiation, progression and therapy.   
 
Materials and Methods 
Healthy single comb white leghorn 1 to 3-year-old laying hens were used in this 
experiment.  All work followed Texas A&M University (TAMU) institutional guidelines 
and was covered under an animal use protocol approved by TAMU Animal Care and 
Use Committee (IACUC).   The laying hens were single housed in laying cages at the 
TAMU poultry research center and provided feed and water ad libitum with a lighting 
schedule permissive of normal egg laying (approx. 16-18 h of light/day).  On the day of 
procedures, hens were transported in dog crates to the surgical suite in a climate 
controlled vehicle and group housed until their procedure.  Hens were anesthetized using 
a mask with isoflurane delivered at 5% until fully anesthetized and maintained at 2.5-
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3.5% thereafter.   Hens were kept on a circulating warming pad for the duration of the 
procedure.  Feathers were removed from the left side of the chest and the surgical area 
was scrubbed with betadine followed by alcohol (repeated 3x). Using a sterile field and 
sterile surgical instruments a 1.5 - 2.5 cm incision was made in the skin and through the 
left side body wall just caudal to the last rib as this is the location of the active ovary in a 
hen. The pre-sterilized port was placed into the incision site and sutured into the body 
wall and the skin using 2-0 polydioxanone suture (PDS).  The birds were recovered by 
removing isoflurane and administering 1 mg/kg buprenorphine IM. Post-operatively 3 
mg/kg carprofen was administered SC to provide pain relief for 12 hours. After that 
time, birds were evaluated daily for evidence of a need for pain medication based on 
limping, not bearing weight, not rousing, holding wing down, holding leg up, lack of 
defecation, lack of activity/lethargy.  The incision was closed using PDS suture. 
Anesthesia for the laparoscopy via the port was the same as for the port implant surgery.  
A laparoscope (Portascope.com, Inc) with a rigid head 4mm head was lubricated with 
sterile ointment, inserted through the self-sealing port and the ovary was visually 
observed or biopsied.  Birds readily recovered after removal of isoflurane and were 
returned to their home cage after completion of the procedures.   
 
Results 
Throughout the course of this study surgical techniques and port design were continually 
improved.  Early stage designs allowed for only 2-4 weeks before the port popped out of 
the body wall due to healing and formation of granulated tissue.  When properly 
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anchored, all late design silicone, self-sealing ports remained in place for over a year of 
placement with no detrimental effects on laying, normal activity, or mobility of the hens.  
Hens actively laying at the time of surgery continued laying after port placement.  It was 
common to see hens lay an egg on the day of surgery (or during) and continue laying 
daily post-operatively indicating minimal impact on the hen from the stress of the 
surgical procedure, anesthesia and port.  Recovery from surgery was very rapid and 
generally within 1 h from the procedure the hen was back in her home cage with the 
ability to eat, drink and be fully weight bearing.  Necropsies performed by a board 
certified veterinary pathologist at one-year post port placement revealed only mild tissue 
tacking from the caudal thoracic air sac to the port.  Tissue surrounding the port looked 
healthy and the port was fully intact and the seal patent.  The current device allows for 
routine access for evaluation and biopsy of organs in the coelomic cavity, specifically 
the ovarian tissue.   
 
Discussion 
Port design was modified over 1.5 years with changes to shape, material, texture, ability 
to hold suture and plug removability.   The port concept was originally thought of as an 
animal procedural refinement with the overall number of surgical events being reduced 
to simple anesthetic events for the hen.  This refinement also reduced the overall 
numbers of hens utilized in our research.   The IACUC set a limit on the number of 
surgical events a research animal could undergo in its lifetime.  With the laying hen 
having a wide range in years to onset of ovarian cancer, it seemed impractical to limit 
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the number of laparoscopic procedures over the range of 2-7 years.  After brainstorming 
with veterinarians, the concept was developed to use a permanent “port” that would 
mirror a rumen cannula used in cattle (Fig. 1).  Commercial devices for use in poultry 
were not available.  Producers of rumen cannulae do not make a product small enough 
for a 1.5kg animal.   
 
 
 
 
 
 
 
 
 
 
Human pediatric devices were considered; however, no product fit the size required for 
the hen, or the accessibility of the laparoscope.  Polycarbonate bottle tops and rubber 
grommets sealed with an internal plug were investigated, but adequate functionality and 
size parameters of both grommets and plugs were not found (Fig. 2).    
 
 
Fig. 1. Diagram of a typical commercially available flexible 
rumen cannula produced for cows. Typical dimensions in a cow; 
A = center hole diameter (100mm), B = flange width (80mm), 
C= total diameter (250mm). 
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Due to lack of a commercially available product that met our specifications, production 
of a device was discussed with Texas A&M University’s Mechanical Engineering and 
biomedical device specialist Dr. Michael Moreno.  Dr. Moreno’s team included doctoral 
candidate Andrew Robbins who fabricated our device utilizing 3D printing technology.  
Working closely with Dr. Moreno’s team and the laboratory animal veterinarians at 
Texas A&M University’s Comparative Medicine Program, the port design was modified 
over 1.5 years with changes to shape, material, texture, ability to hold suture, and plug 
removability.  The first prototype mimicked a rumen cannula reduced to the size of a 
hen, and this design and plug were completely 3D printed out of biocompatible material 
(Fig. 3).   
Fig. 2. Evolution of the port design.  The port idea was conceived from a device 
that would mimic a rumen cannula scaled to a 1.5 kg hen. 
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The prototype was circular, rigid, and spool shaped, with a central cavity containing a 
removable plug.  The prototype was surgically implanted into a hen and it was well 
tolerated (Fig. 4); however, after 2-4 weeks the port would work its way out of the bird 
due to changes in the surrounding tissues during the normal healing process.    
 
 
 
 
 
 
 
 
   
 
 
Fig. 4. First implanted prototype. Hens tolerated the surgical implant, and within 1h 
of anesthesia they were eating, drinking, moving normally and resuming egg laying. 
Fig. 3.  First 3D printed prototype.  Prototype produced by Texas A&M University’s 
Department of Mechanical Engineering.  
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Granulation tissue formation is a normal process in healing, however, with the shape and 
location of the port the tissue would build up around the port and up through the plug 
opening causing the port to be slowly pushed out.  Further device modifications included 
different materials, shapes and plugs for the device.  Silicone coating over the plug and 
port did not improve the rejection time.  Suture holes were added to improve device 
anchoring however, rejection time was still unchanged.  The shape of the next device 
was modified to be oval to better accommodate the location and limited space between 
the hens last rib and the back leg (Fig. 5). 
 
 
Fig. 5. Suture holes for anchoring during surgery. Suture holes were added to improve 
the oval-shaped port which was more flexible and designed to improve the fit in the hen.  
 
 
The material the port was printed from was simultaneously changed to rigid central 
material that merged into softer more flexible lips surrounding the port.  These changes 
improved surgery implant time; however, the port was still rejected.  It was hypothesized 
that rejection was likely be from a primary design failure.  Rumen cannulas were 
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intended to go into a sealed organ (rumen) and the port for this application only needed 
access to the coelomic cavity. Further brainstorming with CMP veterinarians led to the 
hypothesis that a fully flexible, soft port, with a flat narrow center would encourage 
tissue to heal around the device and allow the laparoscope to pass though the central slit.  
Dr. Moreno’s team made a 3D printed mold to our specifications which enabled a 
flexible, light port to be made from pouring silicone into the mold.  The new design 
made for much more rapid surgery and improved anchoring.  The new design did away 
with the central hole of the previous designs and allowed for a self-sealing opening in 
the center where a laparoscope could easily pass through (Fig. 6).   
 
 
 
 
 
 
 
 
 
 
The silicone port was biocompatible and able to withstand being in the hen for over 1 
year without complications (Fig. 7).  The current design allows for repeat laparoscopic 
Fig. 6.  The silicone self-sealing port. The flexible port was made by pouring 
silicone into a 3D printed mold. 
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procedures for visualization and biopsy.  Laparoscopic images of healthy versus 
cancerous tissue are shown (Fig. 8).   
 
 
 
 
 
 
 
 
Fig. 7.  The final port version. The all-silicone designed port implanted in the hen. 
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Hens with implanted ports were imaged using a combination of modalities including 
computed tomography (CT) and positron emitted topography (PET) and placement 
within the coelomic cavity can be well observed (Fig. 9).    
Fig. 8. Laparoscope photos. Top left and top right images show 
healthy ovarian tissue, and bottom left and bottom right images 
are cystic and cancerous with ascites present. 
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Conclusion 
A silicone device was produced that allows for repeated visualizations of the ovarian 
tissue as well as a means to accurately biopsy tissue of interest. This device has minimal 
impact to the hen and remains functional for extended periods of time.  This novel 
approach to study a spontaneously occurring ovarian cancer animal model allows for 
further research and discoveries to be made in ovarian biology and ovarian cancer.   
 
 
 
 
Fig. 9.  Non-invasive imaging of port.  Left shows computed tomography (CT) 
image of the implanted port, right is with positron emitted tomography (PET) 
image overlay. 
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CHAPTER III 
PRECLINICAL POTENTIAL OF THE LAYING HEN MODEL OF OVARIAN 
CANCER: INVESTIGATION OF NON-INVASIVE IMAGING MODALITIES 
FOR DIAGNOSIS AND EVALUATION OF TREATMENT EFFICACY 
 
Synopsis 
Laying hens spontaneously, and at high incidence, develop ovarian cancer which 
remarkably mimics the development of human ovarian cancer which suggests their 
utility as an animal model for preclinical testing of therapeutics for treatment of ovarian 
cancer.  To further validate this model, and test this hypothesis, we identified a cohort of 
ten 4.5-year-old single comb, white laying hens suspected to be developing ovarian 
cancer.   The cohort of laying hens was treated intravenously with paclitaxel 
chemotherapy for six weeks, and changes in the ovaries assessed using serial imaging at 
0, 3, and 6 weeks of treatment.  After completion of the study, hens were euthanized, 
necropsied, and tissues submitted for histopathology.  Results are indicative of accurate 
diagnosis of cancer via non-invasive imaging and chemotherapeutic efficacy, further 
suggesting the laying hen’s potential for use in preclinical research on ovarian cancer.  
 
Introduction 
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer [41]; the high 
mortality associated with this disease is attributed to late diagnosis, lack of screening 
methods, as well as ineffective treatment and preventative therapies.  In most cases, at 
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the time of diagnosis, a woman has already progressed to late stage cancer with 
metastatic spread outside of the ovaries lending to poor prognosis.   Early detection 
methods of EOC are greatly needed; per the American Cancer Society, only 19% of 
ovarian cancer cases are diagnosed before there is metastatic spread outside the ovary, 
and when diagnosed early a patient’s 5-year survival rate exceeds 90%. 
 
EOC is a very complex disease in part due to the lack of a known cell of origin, variety 
of tumor types, and numerous histotypes.   High-grade serous carcinoma (HGSC) makes 
up more than 70% of the primary EOC.  A complicating factor to diagnosis of this 
disease is these tumors are histologically identical to peritoneal and fallopian tube serous 
tumors.  The standard treatment for HGSC is surgical debulking, followed by a platinum 
and taxane combinatorial chemotherapeutic regimen.  While this treatment shows initial 
efficacy, there is a very high rate of recurrence.   Because of the complexity of EOC, 
there is a need for preclinical models that adequately mirror the heterogeneity inherent 
with the disease.  Mice are the primary model used to study EOC; most commonly either 
xenograft mice, genetically engineered mice, and patient derived xenograft mice are 
used for ovarian cancer research. None of these models are spontaneous, and they do not 
mimic the normal progression of ovarian cancer.  Models must be genetically altered or 
be completely immunodeficient to allow them to propagate human cancer cells without 
rejection.  Each model used to study EOC has its advantages and disadvantages, and 
progress of this deadly disease will likely require more than just a single model to make 
advances.  Unlike many of the mouse models of ovarian cancer, the laying hen has all 
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four histologic subtypes (serous, mucinous, clear cell and endometrioid) that are present 
in humans, in addition to the development of spontaneous ovarian cancer.  
 
Laying hens hold promise as a superior animal model for cancer research.  The laying 
hen is the only animal model that spontaneously develops ovarian cancer at a high 
incidence, which could be key to uncovering the events essential for initiating ovarian 
cancer and for developing early detection and screening techniques.  Laying hens have 
an increasing incidence of ovarian cancer after age 2, which is late in its reproductive 
life, coinciding with that of a post-menopausal woman, whose incidence increases after 
the age of 63.    One of the greatest assets of the laying hen is an estimated tenfold 
greater incidence of ovarian cancer than humans (14, 20).  There is a known link 
between the number of ovulatory events and the incidence of ovarian cancer, although 
the exact mechanism through which this occurs is unknown.  Research has shown that 
decreases in the number of ovulations, as with oral contraceptive use, reduce the risk of 
ovarian cancer in women.  There is a similar trend in laying hens when ovulation is 
inhibited with a progestin, estrogen or a combination of the two [20].   
 
We hypothesize that laying hens, though not fully characterized, are an optimal model 
for the study of human ovarian cancer initiation, progression and therapy.  Lack of a 
method for predicting EOC in laying hens is an obstacle to the utilization of laying hens 
in preclinical studies.  Historically, to establish a study cohort of laying hens, researchers 
must carry out studies on a large scale in hopes of obtaining enough cancerous hens to 
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see statistical significance of a given treatment.    The method we describe here started 
with 20 hens that were subjected to a combination of imaging modalities including 
magnetic resonance imaging (MRI), computed tomography (CT) and positron emitted 
topography (PET) to detect ovarian cancer.   Since these technologies are labor and cost 
intensive, we ran an initial MRI on a 4-year-old and a 1-year-old laying hen to see if we 
could visualize the ovary and compare cancerous and noncancerous ovaries.    The first 
MRI scan revealed that a laying hen with cancerous ovaries was selected for comparison 
to normal ovaries from a young laying hen (Fig. 10).  This validated our identification 
approach.  
 
Fig. 10. Proof of concept magnetic resonance imaging (MRI).  MRI  
T2 coronal image of a cancerous ovary in a 4-year-old laying hen 
(left), and a normal ovary from a 1-year-old healthy laying hen (right).   
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After imaging, 10 hens were selected to proceed through the chemotherapy treatment 
and were staged on a scale of I-IV based on visual abnormalities suggestive of coelomic 
cancer.  Two of the 10 were included as “suspect” without a stage designation.  Since a 
method for staging EOC via these imaging modalities in laying hens does not exist, we 
chose a staging system based on a histopathological approach [42].  Stage I was assigned 
if abnormalities appeared to be confined to the ovary (with some of the ovary having a 
normal phenotype); Stage II involved abnormalities that involved most of the ovary and 
may have oviductal involvement; Stage III involved abnormalities that included the 
whole ovary with other organ involvement possible, with or without ascites fluid 
present; and Stage IV involved extensive peritoneal metastasis and ascites fluid present.   
 
Common standard of care in human patients is a combinatorial therapy of a taxane, such 
as paclitaxel, plus a platinum-based drug, such as carboplatin or cisplatin, for six cycles.   
Due to the limited amount of data on chemotherapeutic doses and tolerability in the 
laying hen or avian species in general, it was decided to use only a single drug that was 
predicted to show efficacy when given alone.  Paclitaxel was the chemotherapeutic 
selected for this study as it is one of the most common chemotherapeutics used to treat 
human ovarian cancer, and under oncologist advisement that this drug, when given 
alone, would be expected to exhibit anti-cancer effects in human patients.  Paclitaxel at 
10mg/kg was determined in our prior studies to be well tolerated for six weekly doses. 
Mass spectrometry results confirmed the presence of paclitaxel in hens administered 
intravenous paclitaxel at 7.5mg, 10mg, and 12.5mg per kilogram (AUC =9.6, 5.7, and 
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3.5 ug/ml per hr respectively) (Fig. 11).  The dose of 10mg/kg is slightly lower than the 
human equivalent dose of 175mg/𝑚2 when taking body surface area into account.  
Frequency of treatment in humans is six rounds with 3 weeks in between each round.  In 
laboratory animals, such as mice, chemotherapy is commonly administered as a single 
bolus intravenous injection on a weekly regimen.   Since this was an attempt to further 
validate the laying hen as a research model, we administered the paclitaxel IV (jugular 
vein) once weekly for 6 weeks.   
 
 
 
 
 
Fig. 11.  Hen tolerability of paclitaxel.  Tolerability was assessed by once weekly IV 
administration of 7.5mg, 10mg, and 12.5mg per kilogram, single bolus, AUC 3.5, 5.7, 
and 9.6 ug/ml per h respectively. 
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Materials and Methods 
The Texas A&M Institute for Preclinical Studies (TIPS) performed MRI and PET/CT 
imaging on 20 4.5-year-old single-comb white leghorn hens to identify 10 candidates for 
ovarian cancer (estimated 60-70% incidence).  The laying hens were identified as cancer 
suspects via abnormalities detected using MRI and PET/CT.  A cohort of 10 laying hens 
was treated with paclitaxel, a common taxane chemotherapeutic (WG Critical Care, 
Paramus, NJ).  Hens were imaged a total of three times (0, 3wk, and 6wk of treatment) 
to assess efficacy and improvements in tumor size and a reduction in ascites fluid. Birds 
were visually assessed daily and weighed weekly during the 6-week treatment period (1x 
weekly chemo regimen) and were monitored for any sign of decreased excrement, 
lethargy, anemia (pale comb/wattle) or breathing abnormalities. Blood samples were 
taken at 0, 3, and 6 weeks to evaluate blood chemistry, specifically, bile acids, a measure 
of liver function in birds, throughout the treatment period (< 0.5 ml blood drawn per 
time point). The hens were placed in a cage and transported in a climate controlled 
vehicle from the poultry science center (POSC) to the TIPS animal loading dock.  
 
After hens arrived in the surgical preparation room, they were examined for health prior 
to dosing with butorphenol (1mg/kg IM) as a pre-anesthetic. Anesthesia in the hens was 
induced and maintained with isoflurane using a vaporizer and nose cone with a charcoal 
scavenging system. Once fully anesthetized, their wing vein was catheterized and 
flushed with heparinized saline to allow access for contrast to be injected into the blood 
stream prior to imaging.  MRI scans were done using a Siemens 3T MRI scanner. After 
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localizer sequences, pre-contrast coronal T2-weighted images with and without fat 
saturation, as well as axial T2-weighted fat-saturated and T1-weighted images were 
obtained. Intravenous contrast was then given (Gadavist 1mMol/ml; 1ml in 5ml NaCl). 
Post-contrast sequences included T1-weighted fat-saturated axial and coronal images.  
The parameters for the T1-weighted sequences included TR of 779 to 973ms and TE of 
11-12ms. The parameters for T2-weighted sequences included TR of 5350 to 7010ms 
and TE of 93-116ms. Slice thickness of 3mm was used for coronal images and 4mm for 
axial images. While in the MRI, under anesthesia, birds were injected with 18F-FDG (5-
10 mCi/kg) approximately 1h prior to CT scan to aid in PET imaging for contrast and in 
identification of hypermetabolic areas.  Feed was withheld the evening prior to the 
procedures and birds were kept in a dark, quiet holding room for 1 hour prior to 
anesthesia to minimize excess digestion and movement.  18F-FDG fluorodeoxyglucose is 
a radiolabeled glucose analog used to identify highly metabolic areas such as those that 
would occur with cancer.  TIPS radiation safety procedures were followed including 
separation of the radioactive materials (containers, animals, feces, syringes and blood) 
until they were cleared by a TIPS radiation safety staff member or radiation permit 
holder.  Hens were analyzed individually under isoflurane anesthesia and moved on a 
transport cart along with the vaporizer to the MRI imaging room where they were 
transitioned to an MRI-safe vaporizer and placed in the magnet.  After MRI scans were 
completed the hen was moved into the CT imaging room, reconnected to a vaporizer and 
maintained on isoflurane until imaging was complete.    For the CT and PET, scans were 
obtained on a 128-slice Siemens Biograph CT/PET scanner. After localizing topograms 
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were acquired, a whole-body pre-contrast CT scan was performed. This was followed by 
acquisition of a whole-body PET scan.  Iodinated CT (omnipaque, 2ml 350mg/ml 
followed by 3ml NaCl) contrast was then given into the venous catheter and a post-
contrast whole body CT scan was obtained.  It took approximately 1.5 hours to image 
each hen using MRI, CT and PET. Supplemental heat was provided by warmed bags of 
rice and MRI-compatible disposable warmers. Monitoring under anesthesia was 
accomplished by using a respiration pillow, fiber optic temperature rectal probe, pulse 
oximetry and a blood pressure cuff (SA Instruments, Stony Brook, NY).  The hens were 
recovered from anesthesia by providing oxygen only via the nose cone and 
administering 35ml warmed fluids (NaCl) subcutaneously.  Hens were returned to their 
cage under a warming lamp, provided feed and water ad libitum and held until cleared 
by the radiation safety officer, and finally transported back to the POSC center and 
placed in their home cages.   
 
Results 
Necropsy of the hens after final imaging revealed that 7 of 10 (70%) hens had metastatic 
cancer, and 3 of 10 (30%) hens were non-cancerous.  The breakdown of the metastatic 
cancer based on histopathology was ovarian carcinoma with metastasis in 6 out of 10 
(60%) hens and 1 of 10 (10%) had oviductal carcinoma with metastasis
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Analysis of MRI and CT images at 0, 3 and 6 weeks of treatment correlate well with 
diagnosing cancer and assessing changes post-treatment within the coelomic cavity of 
the laying hen.  Image analysis throughout the study by board certified avian 
veterinarians accurately observed indications suggestive of the presence of cancer within 
the coelomic cavity in all but one of the hens (#104); in this case the results were 
confounded by the presence of fibrin and yolk masses found on necropsy and 
histopathology.  Although identification of the presence of cancer was accurate, initial 
staging of the hens was performed after only one MRI and CT/PET image collection 
event (timepoint 0).  One-half of the staging assigned at this point correlated well 5/10 
(50%) were accurately assessed late stage cancer; however, we found confounding 
presentation of disease (massive ascites or the presence of fibrin within the coelomic 
cavity) or less than ideal image quality (breathing artifacts and slice size of MRI) led to 
an inaccurate assignment when staging from just a single set of images.  When taking 
3wk and 6wk images into account collectively, stage assessment would have been 
significantly more accurate.  Additionally, 18F-FDG uptake and reflux variability led to 
difficulties making an accurate diagnosis based on standardized uptake value (SUV) 
alone.   Since the 18F-FDG is excreted by the kidney and there can be reflux into the 
cloaca, colon and coecal pouches, it was not always a definitive sign of hyper-
metabolism for cancer diagnostic purposes, however, in instances where a clear mass 
was visible, PET imaging was an effective means of following response to treatment. 
Our study found that MRI was most informative for diagnosis and assessment of 
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changes; however, CT and PET images proved to be helpful methods for clarification of 
MRI findings and to aid identification and progression of cancer in the hen.    
 
Paclitaxel appeared to cause a reduction in ascites fluid, ovarian quiescence, reduction in 
ventriculus dilation, reduction of bowel wall thickness and a reduction in tumor 18F-FDG 
SUV in several hens over the course of treatment (even if only an initial response).  
Ascites fluid was present in 8 out of 10 hens at the start of the study.   Of those 8, (75%) 
showed a reduction in fluid volume in the coelomic cavity (Fig. 12); one additional hen 
(#108) showed a reduction, however, had coelomic tap (ascites removal) performed at 
intervals throughout the study to remove excess fluid, so the reduction cannot solely be 
attributed to the chemotherapeutic regimen alone.   Only one hen had an increase in 
ascites fluid volume throughout the study (#75) and was diagnosed with oviductal 
cancer.   
 
Fig. 12.  Diminished ascites with paclitaxel treatment.  Hen# 61 from left to right MRI 
images at 0, 3wk, 6wk of paclitaxel treatment showing decreased ascites fluid over each 
time point. 
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Ovarian changes throughout the study were quite remarkable and occurred in both the 
cancerous and non-cancerous hens and was attributed to the chemotherapeutic regimen.  
Sixty percent (6 of 10) hens had a notable shift from an active ovary to a completely 
quiescent ovary by the end of the study.  This was also noted in a prior tolerability study 
where 1.5-year-old, actively laying hens given paclitaxel for 6 weeks, showed a dose 
dependent reduction in follicular development over the course of treatment (Fig. 13). 
Fig. 13. Ovarian quiescence with paclitaxel. The left panel show ovaries from laying 
hens receiving once-weekly IV bolus injections of 7.5mg, 10mg, and 12.5mg per 
kilogram dose paclitaxel for 6 weeks had a dose response of ovarian quiescence, with 
histologic confirmation.  The top right panel is an MRI of hen #53, with an active 
ovary with clear F1-F5 follicles, whereas the bottom right panel shows no detectable 
follicles after treatment.  
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Significant dilation of the ventriculus (gizzard) was noted in three hens, one of which 
was shown to have cancer in nearby tissue of the esophagus and proventriculus (#127).  
This ventriculus dilation was suspected to occur from poor gastrointestinal clearance due 
to the presence of cancer that had metastasized to the intestines.  In all three cases, the 
severity of the ventriculus dilation was reduced throughout the 6-week treatment.  This 
reduction in ventriculus dilation can be clearly seen on MRI (Fig. 14). 
 
 
These results show proof of concept of a non-invasive measure that can be used for 
identification of coelomic cancer and assessment of changes due to treatment.  These 
results provide further validation of the laying hen model for preclinical studies of 
ovarian cancer. 
 
Fig. 14.  Reduction in ventriculus dilation with treatment. Hen#22 shown on left 
prior to paclitaxel treatment, on right, after 3 weeks of treatment the ventriculus 
dilation is greatly reduced.   
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Discussion 
The treatment goal of human ovarian cancer is dependent on the stage of cancer.  If 
fortunate enough to be diagnosed at an early stage (occurs in only 20% of cases), the 
focus of treatment is progression free survival, whereas, in late stage diagnosis, the 
objective is palliative care for control of symptoms and pain relief [43].  Our study was 6 
weeks in duration and ended with necropsy of the laying hens therefore, prolonging their 
life span could be the focus of future studies.  The cohort had a 70% survival rate to the 
end of study; one hen (#22) died under anesthesia during the MRI at week 3, and the 
remaining two laying hens (#73, #75) died under anesthesia during the imaging process 
at week 6.   All three hens who died had late stage cancer.  Most treated hens appeared 
physically healthier, better groomed, and more active for the first 5 weeks of treatment, 
which could be attributed to improvements due to chemotherapy, fluid administration 
and/or topical mite treatment during the study.  Some of the observed improvements 
were likely due to reduced ascites and ovarian and follicular atrophy resulting in more 
room within the coelomic cavity allowing for improved gastrointestinal clearance and 
comfort of the hens throughout treatment.  In the 6th and final week, all hens were given 
daily supportive care (30ml saline subcutaneously and 0.5ml Nutrical) during their final 
week due to observations of weight loss in the final week in this and previous tolerability 
studies.   Caution should be used when administering weekly dosing of a paclitaxel 
regimen as the 6th dose seems to be the most difficult for the birds to tolerate, however, 
with monitoring and care, the weight loss is manageable (Fig. 15).  
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Diagnosis of cancer within the coelomic cavity over a single image collection timepoint 
was not an effective method to establish accurate stage of cancer accurately, but images 
correlated well with the presence of cancerous versus non-cancerous hens, especially 
over multiple days of imaging.  Staging multiple image collection sets allows for an 
overall reduction in false results based on breathing artifacts, movement, and fluid flux.   
We found that position of the bird was important for the tolerability of the imaging 
procedure.  Initially, hens were laid on their backs for imaging, however, due to their 
cancerous condition and the presence of ascites fluid, we observed an upright “roosting” 
Fig. 15.  Body weights of hens throughout the paclitaxel treatment. In the final week, 
hens were supplemented with daily subcutaneous fluids and oral gavage of 0.5ml 
nutrical caloric supplement to aid in weight loss. 
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position was optimal for hens.  This was accomplished by using cut out baskets which 
allowed for monitoring equipment connection and a normal resting position in which the 
birds could breathe comfortably (Fig. 16). 
 
 
The MRI provided the most informative measure of disease of all imaging modalities 
used, however, both CT and PET helped clarify findings from MRI.   In the future, it 
may be important to perform dynamic imaging studies to rule out effects of fluid shifts 
(such as cloaca reflux) causing the appearance of areas of high 18F-FDG uptake.  
Additionally, more selective radiolabeled markers may be useful in targeting specific 
areas of ovarian tissues for future studies.  
 
Fig. 16.  Basket for proper positioning during imaging.  Hen in 
“roosting” position for imaging, which accommodated connection 
of the monitoring devices and optimal breathing for hens with 
ascites fluid. 
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The use of MRI in laying hens, and potentially other birds, was useful for visualizing F1-
F5 follicles to determine normal reproductive activity compared to abnormal activity.  
This study showed that birds with active follicles became reproductively quiescent in 
response to treatment with paclitaxel, which is an important finding as these hens are 
hard wired to lay eggs constantly.  MRI also proved useful for visualizing intestinal 
dilatation which improved across treatment in each of the hens affected with this 
abnormality.  MRI further showed its utility for detecting and characterizing the 
pancreas which has been informally reported to be impossible.  Results of this study 
suggest that these imaging modalities have great diagnostic and prognostic potential in 
birds and can be used serially and safely in future studies.   
 
Conclusion 
The results of this study show proof of concept of a non-invasive technique that can be 
used for identification of coelomic cancer and assessment of changes due to treatment 
further validating the laying hen as an animal model for preclinical studies of ovarian 
cancer.  Additionally, the results of this study revealed an ability to correlate neoplasia 
and reproductive disease using non-invasive imaging modalities, as well as the 
tolerability and efficacy of a 6-week 10mg/kg paclitaxel regimen in laying hens.  These 
are valuable tools for the advancement of ovarian cancer research and use by avian 
clinicians in the treatment of client owned birds.  Our work with paclitaxel may provide 
a novel platform to expand knowledge of its mechanism of action, explore the potential 
for improving cancer treatment regimens, investigate its role in off-label uses where the 
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induction of ovarian quiescence may be beneficial or therapeutic in human medicine 
(fertility protection during chemotherapy, etc.).    
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CHAPTER IV 
FUTURE DIRECTIONS AND CONCLUSIONS 
 
Future Directions 
Future directions of our studies may include combining serial MRI imaging and 
laparoscopic techniques for following the progression of ovarian cancer and metastasis 
in the laying hen.  Utilization of the self-sealing port after diagnosis allows for drug 
delivery into the coelomic cavity to mimic intraperitoneal dosing in a human.  Further, 
the port could be used to follow ovarian changes in the hen after diagnosis with MRI.   
 
The port allows for repeated access to the ovary or coelomic cavity for visualization or 
biopsy, but may also be useful in the delivery of directed nanoparticles that could aid in 
identification and imaging of ovarian cancer and metastasis within the hen.  Metastasis is 
a key problem in ovarian cancer and further research needs to be done to determine the 
early events leading up to the shedding and spread of cancer cells from the primary 
tumor throughout the peritoneal cavity in humans and correspondingly, ovarian cancer 
metastasis within the coelomic cavity of hens.    
 
Improved methods are needed for identifying cancerous hens at an early stage, as is true 
for human ovarian cancer patients.  The earlier the diagnosis, the greater a patient’s odds 
are for survival, and in the laying hen, the earlier cancer can be identified the greater the 
ability to design studies with fewer animal numbers and greater statistical significance.  
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Those methods could involve identification of biomarkers in the blood, or protein 
expression in ovarian biopsies collected laparoscopically through the port.   
 
The data generated from MRI and PET/CT holds significant information that could 
benefit many other areas of study that were not the focus of this ovarian study (bone, 
renal, hepatic, cardiac, pancreatic etc.).  Little information exists on aged populations of 
laying hens because they routinely do not survive past 2 years in commercial production 
systems.  MRI studies done in birds, much less 4.5-year-old laying hens, is sparse, and 
the data we collected could benefit multiple areas of radiologic training and research.  
Finding the best outlet for this data will be a pursued as a priority. 
 
Our findings of induction of ovarian quiescence spurs many scientific questions about 
paclitaxel’s use.   There is a great need for optimization of the standard combinatorial 
therapy using paclitaxel and platinum drugs for treatment of human ovarian cancer 
enabling maximum benefit for the patient.  Our work may provide the platform needed 
to further this investigation, as well as aid in the understanding of the full mechanism of 
action of this drug; it is suspected paclitaxel is doing more than just disrupting mitosis, 
which is seen by tumor regression, and not just halting growth.  The potential exists that 
there may be off-label uses for paclitaxel in areas of human medicine where ovarian 
quiescence may provide therapeutic benefit such as a possible treatment to offer ovarian 
protection for future fertility post-cancer treatment.   
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Conclusion 
The fact that decades of ovarian cancer research has not yielded significant 
improvements in incidence and mortality rates of women with ovarian cancer, suggests 
the need for better approaches in studies of ovarian cancer.  I believe that the tools 
currently being employed in research on ovarian cancer are insufficient to allow 
scientists and clinicians to conquer this deadly disease.  The goal of this research project 
was to highlight an animal model that is not used frequently, but shows huge potential 
for offering insights into spontaneously occurring human ovarian cancer.  By further 
validating the laying hen model of ovarian cancer and showing its relevance, research-
friendly nature, and ability to serve as a preclinical model, we hope to draw attention to 
the laying hen as a platform for many future studies that will advance the field of ovarian 
cancer research, and potentially many other areas of avian and human medicine.      
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